The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 30, 2017
Filed:
Sep. 03, 2013
Applicant:
Vtv Therapeutics Llc, High Point, NC (US);
Inventors:
Per Sauerberg, Farum, DK;
Pavel Pihera, Prague, CZ;
Zdenek Polivka, Prague, CZ;
Miroslav Havranek, Prague, CZ;
Ingrid Pettersson, Frederiksberg, DK;
John Patrick Mogensen, Herlev, DK;
Assignee:
vTv Therapeutics LLC, High Point, NC (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/415 (2006.01); A61K 31/5375 (2006.01); C07D 295/112 (2006.01); C07C 59/70 (2006.01); C07C 217/48 (2006.01); C07C 323/16 (2006.01); C07C 323/32 (2006.01); C07D 211/46 (2006.01); C07D 213/30 (2006.01); C07D 231/12 (2006.01); C07D 295/096 (2006.01); C07D 307/79 (2006.01); C07D 333/16 (2006.01); C07D 333/54 (2006.01); C07D 265/30 (2006.01); C07D 213/36 (2006.01); C07D 307/81 (2006.01); C07D 333/20 (2006.01);
U.S. Cl.
CPC ...
C07D 295/112 (2013.01); A61K 31/415 (2013.01); A61K 31/5375 (2013.01); C07C 59/70 (2013.01); C07C 217/48 (2013.01); C07C 323/16 (2013.01); C07C 323/32 (2013.01); C07D 211/46 (2013.01); C07D 213/30 (2013.01); C07D 213/36 (2013.01); C07D 231/12 (2013.01); C07D 265/30 (2013.01); C07D 295/096 (2013.01); C07D 307/79 (2013.01); C07D 307/81 (2013.01); C07D 333/16 (2013.01); C07D 333/20 (2013.01); C07D 333/54 (2013.01); C07C 2101/02 (2013.01);
Abstract
Phenoxy acetic acids and phenyl propionic acids and their use in treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of PPARδ and may be useful for treating conditions mediated by the same.